StockNews.com Downgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Sell

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

Several other equities research analysts have also recently weighed in on AGIO. Royal Bank of Canada decreased their price target on Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. The Goldman Sachs Group upped their price target on shares of Agios Pharmaceuticals from $29.00 to $33.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 9th. Finally, JPMorgan Chase & Co. decreased their target price on Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating for the company in a research note on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals presently has an average rating of “Hold” and an average price target of $35.00.

Agios Pharmaceuticals Stock Down 1.3 %

Shares of AGIO opened at $33.44 on Tuesday. The business has a 50-day simple moving average of $31.05 and a two-hundred day simple moving average of $26.79. Agios Pharmaceuticals has a 12-month low of $19.80 and a 12-month high of $35.50. The stock has a market cap of $1.90 billion, a PE ratio of -5.29 and a beta of 0.81.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.20. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The company had revenue of $8.19 million during the quarter, compared to the consensus estimate of $8.37 million. During the same quarter in the prior year, the firm posted ($1.47) earnings per share. The firm’s revenue was up 46.0% compared to the same quarter last year. On average, equities research analysts expect that Agios Pharmaceuticals will post -4.66 EPS for the current year.

Insiders Place Their Bets

In other news, insider James William Burns sold 2,642 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the sale, the insider now owns 34,518 shares in the company, valued at $1,124,251.26. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider James William Burns sold 2,642 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the sale, the insider now directly owns 34,518 shares of the company’s stock, valued at $1,124,251.26. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Brian Goff sold 4,156 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $135,360.92. Following the completion of the transaction, the chief executive officer now directly owns 53,780 shares in the company, valued at approximately $1,751,614.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,889 shares of company stock worth $445,716. Corporate insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AGIO. Mirae Asset Global Investments Co. Ltd. lifted its stake in Agios Pharmaceuticals by 0.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 314 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in Agios Pharmaceuticals by 1.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock valued at $911,000 after buying an additional 540 shares during the period. Teacher Retirement System of Texas grew its position in Agios Pharmaceuticals by 5.3% during the third quarter. Teacher Retirement System of Texas now owns 15,770 shares of the biopharmaceutical company’s stock worth $390,000 after buying an additional 788 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Agios Pharmaceuticals by 9.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock worth $255,000 after acquiring an additional 942 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in Agios Pharmaceuticals by 9.0% in the first quarter. ProShare Advisors LLC now owns 13,917 shares of the biopharmaceutical company’s stock valued at $407,000 after purchasing an additional 1,152 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.